An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
VBI Vaccines Announces Presentation of Physician-Initiated Compassionate Use Data of its 3-Antigen Hepatitis B Vaccine at the 2022 International HBV Meeting
VBI Vaccines Announces Presentation of Physician-Initiated Compassionate Use Data of its 3-Antigen Hepatitis B Vaccine at the 2022 International HBV Meeting
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
VBI Vaccines Inc. (Nasdaq: VBIV) announced the presentation of data from a compassionate use study of its 3-antigen hepatitis B vaccine at the 2022 International HBV Meeting in Paris on September 19. The study involved four adults chronically infected with hepatitis B virus. The vaccine, which includes three surface antigens of HBV, is approved in the US, EU, UK, and Israel. With over 290 million people infected globally, hepatitis B presents a significant health challenge, leading to severe liver disease and related deaths annually.
Positive
Presentation of promising data from compassionate use study of 3-antigen hepatitis B vaccine.
VBI's vaccine is the only 3-antigen hepatitis B vaccine approved in major markets.
Negative
None.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that data from the physician-initiated compassionate use of VBI’s 3-antigen hepatitis B vaccine in four adults chronically infected with hepatitis B virus (HBV) were presented in a poster session at the 2022 International HBV Meeting in Paris, France, on September 19.
Poster Presentation Details
Title: Therapeutic vaccination of chronically HBV infected patients with low-level of HBsAg using a combination of a third generation PreS/S vaccine (Sci-B-Vac™) and a nucleoside analogue
Session: Poster Session I
Date: Monday, September 19, 2022
Presenter: Hedwig Roggendorf, M.D., Institute of Molecular Immunology and Experimental Oncology, University Hospital Rechts der Isar, Technical University of Munich
The poster is archived on the Posters page in the News & Resources of VBI’s website, here.
About Hepatitis B
Hepatitis B is one of the world’s most significant infectious disease threats with more than 290 million people infected globally. HBV infection is the leading cause of liver disease and, with current treatments, it is very difficult to cure, with many patients going on to develop liver cancers. An estimated 900,000 people die each year from complications of chronic HBV such as liver decompensation, cirrhosis, and hepatocellular carcinoma.
About VBI’s 3-Antigen Hepatitis B Vaccine
VBI’s vaccine is the only 3-antigen hepatitis B vaccine, comprised of the three hepatitis B surface antigens of the hepatitis B virus – S, pre-S1, and pre-S2. It is approved for use in the United States, the European Union/European Economic Area, the United Kingdom, and Israel.
About VBI Vaccines Inc.
VBI Vaccines Inc. (“VBI”) is a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease. Through its innovative approach to virus-like particles (“VLPs”), including a proprietary enveloped VLP (“eVLP”) platform technology, VBI develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. VBI is committed to targeting and overcoming significant infectious diseases, including hepatitis B, coronaviruses, and cytomegalovirus (CMV), as well as aggressive cancers including glioblastoma (GBM). VBI is headquartered in Cambridge, Massachusetts, with research operations in Ottawa, Canada, and a research and manufacturing site in Rehovot, Israel.
Cautionary Statement on Forward-looking Information
Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are forward-looking information within the meaning of Canadian securities laws (collectively, “forward-looking statements”). The Company cautions that such statements involve risks and uncertainties that may materially affect the Company’s results of operations. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including but not limited to, the impact of general economic, industry or political conditions in the United States or internationally; the impact of the ongoing COVID-19 pandemic on our clinical studies, manufacturing, business plan, and the global economy; the ability to successfully manufacture and commercialize PreHevbrio/PreHevbri; the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of pipeline candidates and the commercialization of PreHevbrio/PreHevbri; the ability to obtain appropriate or necessary regulatory approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; the Company’s ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to the Company’s products. A discussion of these and other factors, including risks and uncertainties with respect to the Company, is set forth in the Company’s filings with the SEC and the Canadian securities authorities, including its Annual Report on Form 10-K filed with the SEC on March 7, 2022, and filed with the Canadian security authorities at sedar.com on March 7, 2022, as may be supplemented or amended by the Company’s Quarterly Reports on Form 10-Q. Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. All such forward-looking statements made herein are based on our current expectations and we undertake no duty or obligation to update or revise any forward-looking statements for any reason, except as required by law.
